Contact this trialFirst, we need to learn more about you.
Monoclonal Antibodies
Ocrelizumab for Multiple Sclerosis
Recruiting2 awardsPhase 4
New York, New York
This trial is testing whether it is necessary to keep receiving the drug ocrelizumab to prevent relapses in patients with early RRMS. 600 mg of ocrelizumab is given at days 0 and 14, then every 6 months for the next 2 years. At month 12, patients are randomized to one of three groups: Arm 1 receives placebo infusions every 6 months; Arm 2 switch to placebo infusions after month 24; Arm 3 continues receiving ocrelizumab every 6 months. The treatment period will be for a total of 48 months.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.